---
schema_version: '1.0'
id: news-20260828-0b3fc0
title: 米Replimune社、3度目の申請で腫瘍溶解性ウイルス療法の迅速承認を取得
url: https://bio.nikkeibp.co.jp/atcl/news/p1/26/08/21/14931/
url_hash: 0b3fc0d2b3a6078ef0c99804748833c28f5d33d657ca5640822a6fba3886021f
canonical_url: https://bio.nikkeibp.co.jp/atcl/news/p1/26/08/21/14931
source: bio.nikkeibp.co.jp
category: news/health
category_raw: health
region: null
tags:
- health
- medicine
- cancer_treatment
lang: null
published_at: null
fetched_at: '2026-08-28T03:47:13.017756Z'
updated_at: '2026-08-28T04:22:39Z'
status: published
content_hash: null
content_changed_at: null
license_note: link-only
summary: null
summary_source: null
summary_en: null
summary_omitted_reason: license_restricted
redistribution: false
keywords_en:
- cancer_treatment
- health
- Healthify
- medicine
- news
- Replimune
- U.S. medicines
entities_en:
- name: Healthify
  type: organization
- name: U.S. medicines
  type: product
topics_en:
- news
numeric_facts: []
entities:
- name: Healthify
  type: organization
- name: U.S. medicines
  type: product
key_facts: []
related: []
related_auto:
- name: Berry_Street
  type: organization
  weight: 1.0
- name: Tushar_Vashisht
  type: person
  weight: 1.0
computed_at: '2026-08-28T04:22:29Z'
---

# 米Replimune社、3度目の申請で腫瘍溶解性ウイルス療法の迅速承認を取得

## TL;DR
（要約なし・原文はリンク先を参照 / No summary available; see the source link.）

## Key Points
- health / medicine / cancer_treatment

## Details
(本文なし。リンク先参照)

## Source
元記事: [米Replimune社、3度目の申請で腫瘍溶解性ウイルス療法の迅速承認を取得](https://bio.nikkeibp.co.jp/atcl/news/p1/26/08/21/14931/)